4.6 Article

The successful combination of grapefruit juice and venetoclax in an unfit acute myeloid leukemia patient with adverse risk: A case report

期刊

FRONTIERS IN ONCOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.912696

关键词

grapefruit; venetoclax; AML; acute myeloid leukaemia; unfit; adverse risk

类别

资金

  1. National natural science foundation
  2. [81900118]

向作者/读者索取更多资源

Venetoclax combined with hypomethylating agents is the standard treatment for elderly AML patients who are not suitable for intensive therapy. However, the high cost of venetoclax often leads to financial difficulties for patients. This study explored a regime using low-dose venetoclax, azacitidine, and grapefruit juice in an unfit AML patient with TP53 mutation, and achieved successful remission.
Venetoclax combined with hypomethylating agents such as azacitidine and decitabine is the standard regime for the elderly patient with acute myeloid leukemia (AML) unfit for intensive induction therapy. However, many patients struggle with finances and forgo treatments due to the high costs of venetoclax. In this study, we performed the regime with azacitidine, low-dose venetoclax, and grapefruit juice on an unfit AML patient with TP53 mutation. The peak venetoclax concentration (C-max) and side effects on the patient were also monitored. The patient achieved complete remission with the venetoclax C-max within the effective concentration range (1,000-3,000 ng/ml) and maintained durable remission until recently. Febrile neutropenia, thrombocytopenia, and pneumonia appeared during the first cycle and were recovered by stimulating agents and antibiotic treatment. This improvement combination approach by drug-food interaction may enlighten other similarly patients with AML, especially those in low-middle income countries.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据